STOCK TITAN

Adc Therapeutics SA - ADCT STOCK NEWS

Welcome to our dedicated news page for Adc Therapeutics SA (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics SA.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adc Therapeutics SA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adc Therapeutics SA's position in the market.

Rhea-AI Summary
ADC Therapeutics SA (ADCT) announced that ZYNLONTA® in combination with rituximab demonstrated a 96% overall response rate and 85% complete response rate in patients with relapsed or refractory follicular lymphoma. The data was presented at the 65th American Society of Hematology Annual Meeting and Exposition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
-
Rhea-AI Summary
Sobi® to Present New Data at ASH 2023 Annual Meeting: Sobi is proud to present new data at the 65th Annual Meeting of the American Society of Hematology (ASH) in San Diego. The presentation will cover analyses in patients with haemophilia A, paroxysmal nocturnal hemoglobinuria, immune thrombocytopenia, relapsed or refractory diffuse large B-cell lymphoma, myelofibrosis, and haemophagocytic lymphohistiocytosis. The company will introduce Efanesoctocog Alfa for haemophilia A, Empaveli for paroxysmal nocturnal hemoglobinuria, and Doptelet for immune thrombocytopenia. The presentation will also include data on Zynlonta for relapsed or refractory diffuse large B-cell lymphoma, Vonjo for myelofibrosis, and Gamifant for haemophagocytic lymphohistiocytosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
conferences
-
Rhea-AI Summary
ADC Therapeutics SA (NYSE: ADCT) received a notice from the NYSE for not meeting the minimum share price requirement but has a six-month cure period to regain compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.99%
Tags
none
Rhea-AI Summary
ADC Therapeutics reported $14.3 million in net sales for ZYNLONTA® in 3Q 2023, a 33.1% decrease from 3Q 2022. Operating expenses decreased 23% year-over-year. The company expects cash runway into mid-2025. The prioritized pipeline is progressing, with initial data readouts from LOTIS-7 and studies of ADCT-601 and ADCT-901 expected in 1H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.99%
Tags
-
Rhea-AI Summary
ADC Therapeutics CEO, Ameet Mallik, to participate in a fireside chat at the Jefferies London Healthcare Conference on November 14th. The webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.87%
Tags
conferences
-
Rhea-AI Summary
ADC Therapeutics announced that abstracts on ZYNLONTA® have been accepted for presentation at the 65th ASH Annual Meeting. The presentations will highlight the clinical utility of ZYNLONTA as a single agent and in combination with other treatments. Initial results of a Phase 2 study evaluating ZYNLONTA in combination with rituximab in patients with relapsed or refractory follicular lymphoma will also be presented. The combination showed a 95% overall response rate at week 12 and an 86% metabolic complete response rate at week 21.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.32%
Tags
none
Rhea-AI Summary
ADC Therapeutics to host conference call and webcast to report Q3 2023 financial results and provide business updates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
conferences earnings
-
Rhea-AI Summary
ADC Therapeutics CEO to participate in investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.38%
Tags
conferences
-
Rhea-AI Summary
ADC Therapeutics announces updated safety run-in results from Phase 3 trial and study design of LOTIS-7 trial for ZYNLONTA® at SOHO 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
ADC Therapeutics SA (ADCT) reported an 11% increase in ZYNLONTA net sales in the second quarter of 2023, reaching $19.2 million. Operating expenses decreased by 20% year-over-year, and the company's pipeline is advancing with data readouts from clinical trials expected in 2024. The company also announced its plan to discontinue the Phase 2 LOTIS-9 trial for ZYNLONTA. Despite these developments, the company's net loss was $47.1 million for the quarter, compared to $64.4 million in the same quarter of 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.89%
Tags
Adc Therapeutics SA

NYSE:ADCT

ADCT Rankings

ADCT Stock Data

366.43M
62.97M
29%
41.17%
1.2%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Switzerland
Epalinges

About ADCT

adc therapeutics is a biotechnology company located in lausanne, vaud, switzerland.